Monday, September 11, 2017 10:16:44 PM
Hi Flipper,
My concern with the presentation was that it wasn't updated. See slide 11 where it says "Minimum OS threshold anticipated to be reached in first half of July/mid-summer (approx. 2 OS events per month)."
One can't say "anticipated to be reached" (which means looking forward to) for something in July, when it's already the end of August.
I think I'm the only one who has pointed this out - and to me, it's not minor: the presentation slides are not current.
I don't know what to expect at this point. We're all trying to put the pieces together as best we can, and I encourage everyone to keep digging and trying to connect the dots, good or bad.
At this point I'm staying long. LP will speak 2 weeks from Wednesday. People who have waited for years will no doubt wait a little longer. Thanks to all - it's been a long trip and everyone is weary.
My concern with the presentation was that it wasn't updated. See slide 11 where it says "Minimum OS threshold anticipated to be reached in first half of July/mid-summer (approx. 2 OS events per month)."
One can't say "anticipated to be reached" (which means looking forward to) for something in July, when it's already the end of August.
I think I'm the only one who has pointed this out - and to me, it's not minor: the presentation slides are not current.
I don't know what to expect at this point. We're all trying to put the pieces together as best we can, and I encourage everyone to keep digging and trying to connect the dots, good or bad.
At this point I'm staying long. LP will speak 2 weeks from Wednesday. People who have waited for years will no doubt wait a little longer. Thanks to all - it's been a long trip and everyone is weary.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
